New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
08:55 EDTNVS, NVS, NVS, PG, PG, PGFDA to hold a public hearing
The FDA holds a public hearing on the Over-the-Counter Drug Monograph System at FDA Silver Spring, Maryland offices on March 25-26 at 9 am. Webcast Link
News For NVS;PG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
12:38 EDTPGOptions with increasing volume
Options with increasing volume: PG CONN NQ S JNPR MNST ANF
11:49 EDTPGProcter & Gamble calls active on renewed activist investor speculation
Procter & Gamble May 79.5 and 80 calls are active on total call volume of 19K contracts (1K puts) on renewed speculation Nelson Peltz's Trian Partners has taken stake in the company. May weekly call option implied volatility is at 15, June is at 13, July is at 12; compared to its 52-week range of 10 to 19. Active call volume suggests traders taking positions for upside price movement.
11:43 EDTPGRumor: Procter & Gamble active on renewed activist investor speculation
Procter & Gamble shares are active on renewed speculation Nelson Peltz's Trian Partners has taken stake in the company.
08:32 EDTNVSNovartis entered into collaboration with Rani Therapeutics, Reuters says
Subscribe for More Information
07:33 EDTNVSIncyte says clinical portfolio to be featured in 23 abstract presentations
Incyte Corporation (INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis (NVS) and independent investigators, will be presented at the 2015 American Society of Clinical Oncology and European Hematology Association annual meetings. These conferences will take place from May 29th – June 2nd in Chicago, IL and June 11th – 14th in Vienna, Austria. “The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis,” stated Rich Levy, MD, Incyte’s Chief Drug Development Officer. “Incyte is committed to translating R&D excellence into new medicines which can improve patients’ lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.”
05:22 EDTNVSNovartis to present data on 21 medicines, 11 investigational compounds at ASCO
Subscribe for More Information
May 26, 2015
06:24 EDTPGL'Oreal not interested in buying P&G's Wells business, Reuters reports
Subscribe for More Information
May 22, 2015
13:49 EDTPGHenkel seen in lead for Procter & Gamble's Wella brand, Bloomberg says
Subscribe for More Information
12:48 EDTPGHenkel seen in lead for Procter & Gamble's Wella brand, Bloomberg says
Subscribe for More Information
10:52 EDTNVSJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
08:12 EDTPGProcter & Gamble should consider break-up, says Bernstein
Subscribe for More Information
May 21, 2015
10:26 EDTPGDesigner Parfums, LUXE Brands to purchase Frederic Fekkai brand from P&G
Designer Parfums and LUXE Brands announced they have collaborated to form a joint venture to acquire the Frédéric Fekkai luxury hair care brand and salons from Procter & Gamble, effective June 30. The Fekkai business comprises a range of hair products and seven salons in New York, Connecticut, Florida, Texas and California. Approximately 225 people are currently employed in the salon business; they are expected to transfer to the newly formed entity.
08:39 EDTNVSNovartis initiates Phase 1 PCA062, triggering milestone payment to ImmunoGen
In a regulatory filing, ImmunoGen disclosed Novartis (NVS) Institutes for BioMedical Research notified ImmunoGen (IMGN) that Novartis had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5M milestone payment to ImmunoGen.
05:19 EDTNVSNovartis Afinitor extended PFS in Phase III trial in GI or lung origin NET
Novartis announced that the Phase III study of Afinitor tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors, or NET, of gastrointestinal, or GI, or lung origin met its primary endpoint: significant extension of progression-free survival, or PFS, compared to placebo plus best supportive care. The RADIANT-4 study is part of one of the largest clinical trial programs in NET.
May 20, 2015
11:36 EDTNVSNovartis says COPD programs met endpoints in Phase III study
Subscribe for More Information
May 19, 2015
08:57 EDTNVSLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:55 EDTNVSGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
12:29 EDTNVSCorium announces publication of data for needle-free transdermal flu vaccine
Corium International announced the publication of "promising" data on the use of its needle-free transdermal system to deliver influenza vaccine in the June 9 issue of Vaccine. The manuscript, entitled "Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs," details results of a preclinical study conducted by Novartis Vaccines (NVS) and Corium. The results demonstrate the compatibility of Corium's MicroCor needle-free transdermal system with cell culture-derived influenza vaccines, and establish its potential as a next-generation vaccine delivery system, the company said.
08:52 EDTPGProcter & Gamble removed from US Focus List at Credit Suisse
Subscribe for More Information
07:38 EDTNVSNovartis outlook has improved, says Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use